Tumor-specific neoantigen peptide presented on major histocompatibility complex molecule (Neoantigen peptide-MHC complex)

Tumor-specific neoantigen peptides presented on major histocompatibility complex molecules are short protein fragments generated from tumor-specific genomic alterations—such as point mutations, indels, alternative splicing, gene fusions, or post-translational modifications—that are processed by the tumor cell and displayed on its surface by MHC class I or II molecules[1][2][3][4][5][6]. Their unique origin makes them absent from normal tissues, allowing the immune system, particularly T cells, to specifically recognize and respond to cancer cells harboring these neoantigens[1][3][4][5]. Therapeutic approaches exploiting these targets include personalized neoantigen vaccines, adoptive T cell therapies, and predictive biomarker strategies for immune checkpoint blockade response[2][3][5]. The identification, validation, and targeting of neoantigen peptide-MHC complexes represent a critical frontier in precision cancer immunotherapy, though challenges remain regarding tumor heterogeneity, immune escape, and accurate immunogenicity prediction[1][2][3][5][6].

Other names

Tumor-specific neoantigenNeoepitopeTumor-specific antigen (TSA)NeoantigenMHC-presented neoantigen peptideCancer-specific MAP (MHC-associated peptide)

Drugs targeting neoantigen peptide-MHC complexes induce tumor-specific T cell recognition and killing by enhancing immune system recognition of tumors not previously seen as foreign. This is achieved by presenting truly foreign peptides on cancer cells (not present in normal tissues), leading to the activation and expansion of neoantigen-reactive cytotoxic CD8+ T cells (via MHC-I) or helper CD4+ T cells (via MHC-II).